Cognition Therapeutics (CGTX) Discusses Path Toward Registrational Trial for Dementia With Lewy Bodies

Cognition Therapeutics recently met with the FDA to discuss Phase 2 results of zervimesine and a potential registrational trial in dementia with Lewy bodies accompanied by psychosis. The company also reported Q1 2026 financials showing reduced losses compared to the prior year.

By Laiba Immad Tue, June 2, 2026 at 4:56 PM GMT+3 2 min read · Yahoo Finance · June 2, 2026, 13:56 UTC

Topics: biotech dementia with lewy bodies (DLB) financial results pharma registrational trial

Read the full article at Yahoo Finance

More World news

Nvidia Shares Decline Following Resignation of CEO Jensen Huang Seeking Alpha · November 12, 2026, 16:07 UTC
Broadcom and Micron Identified as Top Alternatives to Nvidia Amid Leadership Uncertainty Motley Fool · November 12, 2026, 16:03 UTC
Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC